Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) Short Interest Down 57.4% in November

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) was the target of a large decrease in short interest in November. As of November 15th, there was short interest totalling 14,600 shares, a decrease of 57.4% from the October 31st total of 34,300 shares. Based on an average daily volume of 254,600 shares, the short-interest ratio is presently 0.1 days.

Chugai Pharmaceutical Stock Up 3.8 %

Shares of OTCMKTS:CHGCY traded up $0.80 during trading on Thursday, hitting $21.63. 56,222 shares of the stock traded hands, compared to its average volume of 128,906. The company has a fifty day moving average price of $23.30 and a two-hundred day moving average price of $20.80. Chugai Pharmaceutical has a 52-week low of $14.52 and a 52-week high of $26.00. The company has a market cap of $71.16 billion, a price-to-earnings ratio of 27.73 and a beta of 0.89.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.